atrial fibrillation – Page 6

Dynamic Triglyceride-Glucose Index Trajectories as Predictors of Mortality in Critically Ill Patients with Atrial Fibrillation

By MedXY 08/21/2025

A retrospective study shows high and fluctuating triglyceride-glucose (TyG) index trajectories predict increased short- and long-term mortality in ICU patients with atrial fibrillation, highlighting TyG dynamics as a valuable prognostic biomarker.

Cardiology news Specialties

Dynamic Triglyceride-Glucose Index Trajectories Predict Mortality in Critically Ill Atrial Fibrillation Patients

By MedXY 08/21/2025

This study reveals that fluctuating high triglyceride-glucose (TyG) index trajectories in critically ill atrial fibrillation patients significantly predict increased all-cause mortality up to one year post-ICU admission, offering a novel prognostic tool for risk stratification.

Cardiology Specialties

Optimizing Anticoagulant Therapy in Frail Elderly AF Patients: Insights from the COMBINE-AF Substudy

By MedXY 08/17/2025

Switching frail, elderly atrial fibrillation patients from warfarin to standard-dose DOAC reduced stroke, fatal and intracranial bleeding, and death, though gastrointestinal bleeding increased. Major bleeding and net clinical outcome remained similar.

Cardiology Specialties

Marshall-Plan Ablation Strategy Versus Pulmonary Vein Isolation in Persistent AF

By MedXY 08/17/2025

This study compares the effectiveness of the Marshall-Plan ablation strategy against pulmonary vein isolation for treating persistent atrial fibrillation.

Cardiology news Specialties

Higher Risk of Major Gastrointestinal Bleeding with Edoxaban vs Warfarin After TAVR: Insights from the ENVISAGE-TAVI AF Trial

By MedXY 08/17/2025

The ENVISAGE-TAVI AF trial found that patients with atrial fibrillation undergoing TAVR had a higher incidence of major gastrointestinal bleeding when treated with edoxaban compared to warfarin, highlighting the importance of risk factor identification.

Cardiology news Specialties

Optimizing Sedation for Pulsed-Field Ablation in Atrial Fibrillation: Results of the COOPERATIVE-PFA Trial

By MedXY 08/17/2025

This randomized trial compares sedation regimens for pulsed-field ablation in atrial fibrillation, finding remimazolam-ketamine deep analgosedation superior to propofol-opioid approaches in reducing hypoxemia and hypotension.

Cardiology Clinical Updates news Specialties

Abelacimab vs. Rivaroxaban in Atrial Fibrillation Patients on Antiplatelet Therapy: Insights from the AZALEA-TIMI 71 Trial

By MedXY 08/16/2025

The AZALEA-TIMI 71 trial shows abelacimab, a novel factor XI inhibitor, reduces bleeding risk compared to rivaroxaban in atrial fibrillation patients on antiplatelet therapy, suggesting a safer anticoagulation alternative.

Cardiology Clinical Updates Nephrology Neurology news Specialties

OPTIMAS Trial: Early vs. Delayed Anticoagulation in Acute Ischemic Stroke with Atrial Fibrillation and Chronic Kidney Disease

By MedXY 08/13/2025

The OPTIMAS trial shows that chronic kidney disease does not alter the safety or efficacy of early direct oral anticoagulant use after acute ischemic stroke with atrial fibrillation, supporting early initiation regardless of kidney status.

Cardiology Clinical Updates news Specialties

Balancing Stroke Prevention and Bleeding Risk: Timing of DOAC Restart After Serious Bleeding in Atrial Fibrillation

By MedXY 07/31/2025

Early resumption of DOACs after serious bleeding in AF patients may lower stroke risk but significantly increases recurrent bleeding. Individualized decision-making and further research are recommended.

Cardiology Medical News Specialties

Long Daytime Naps and Short Nighttime Sleep Linked to Triple the Risk of Atrial Fibrillation: Insights from a Spanish Cohort Study

By MedXY 07/29/2025

Extended daytime naps and inadequate nighttime sleep independently and synergistically elevate the risk of incident atrial fibrillation, according to a large Spanish cohort study.